OncLive TV

Dr. DiSilvestro on 7-Year Follow up of Olaparib Maintenance in Advanced Ovarian Cancer

September 12th 2022

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

Dr. Strickler on the Results of Tucatinib Monotherapy in HER2+ CRC

September 12th 2022

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

Dr. Patel on the Neoadjuvant Administration of Pembrolizumab in Advanced Melanoma

September 11th 2022

Sapna Patel, BA, MD, discusses the neoadjuvant administration of pembrolizumab in advanced melanoma.

Dr. Petrylak on Enzalutamide Plus Androgen Deprivation Therapy in mHSPC

September 11th 2022

Daniel P. Petrylak, MD, discusses enzalutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer.

Dr Allaf on Perioperative Nivolumab Vs Observation Following Nephrectomy in RCC

September 10th 2022

Mohamad Ezzeddine Allaf, MD, discusses the results of perioperative nivolumab vs observation in patients with renal cell carcinoma who undergo nephrectomy.

Dr. Ornstein on Toxicity Concerns for Neoadjuvant Therapy in Localized RCC

September 9th 2022

Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.

Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL

September 9th 2022

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Dr. Yarchoan on Gemcitabine and Cisplatin Combination Therapy Biliary Tract Cancer

September 8th 2022

Mark Yarchoan, MD, discusses the addition of durvalumab (Imfinzi) to gemcitabine and cisplatin in biliary tract cancer.

Dr. Martin-Broto on Future Research Directions of Soft Tissue Sarcoma

September 8th 2022

Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.

Dr. Conlin on the Practice-Changing Data of Trastuzumab Deruxtecan in HER2+ Breast Cancer

September 7th 2022

Alison K. Conlin, MD, discusses the practice-changing data of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Shah on Evaluating AUTO1 in Relapsed/Refractory B-Cell ALL

September 7th 2022

Dr. Roychowdhury on FGFR Mutations in Intrahepatic Cholangiocarcinoma

September 7th 2022

Sameek Roychowdhury, MD, PhD, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma.

Dr. Litton on Remaining Questions in ESR1-Mutated Breast Cancer

September 7th 2022

Jennifer Keating Litton, MD, discusses research areas of interest in ESR1-mutated, endocrine receptor–positive, HER2-negative breast cancer.

Dr. Kim on the Role of Biomarker Testing in Treatment Decisions for Solid Tumors

September 7th 2022

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

September 2nd 2022

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Dr. Kaklamani on the Use of Adjuvant Olaparib in Germline BRCA1/2-Mutant Breast Cancer

September 2nd 2022

Virginia G. Kaklamani, MD, discusses the use of adjuvant olaparib in germline BRCA1/2-mutant breast cancer.

Dr. Langer on the Benefit of Atezolizumab Following Progression in Advanced NSCLC

September 1st 2022

Corey J. Langer, MD, discusses the benefit observed with the continued treatment of atezolizumab following disease progression in patients with advanced non–small cell lung cancer.

Dr. Herbst on Considerations for Frontline Immunotherapy in NSCLC

September 1st 2022

Roy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.

Dr. Winestone on Disparities with Diagnosis in Pediatric Leukemia

August 31st 2022

Lena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.

Dr. Kim on Clinical Implications of ADCs in HER2+ Solid Tumors

August 31st 2022

Edward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.